CMTX-101
Brief description of study
Determine safety and tolerability of IV administered doses of CMTX-101. Determine safety and tolerability of IV administered doses of CMTX-101. Assess the PK of different doses of CMTX-101. Evaluate immunogenicity (i.e., development of anti-drug antibodies [ADA] and neutralizing antibodies [Nabs]) of a single IV administered dose of CMTX-101. Assess the reduction of P. aeruginosa pulmonary burden following inhaled tobramycin.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
